Andrew David Levin - 11 Jun 2026 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Reporting relationship: Director
Issuer ticker: VOR
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 20:39:46 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Adi Osovsky, Attorney-in-Fact

Key filing fact

Andrew David Levin filed Form 4 for Vor Biopharma Inc. (VOR) on 12 Jun 2026.

Key facts

This page summarizes Andrew David Levin's Form 4 filing for Vor Biopharma Inc. (VOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 20:39.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867539 Primary reporting owner

Levin Andrew David

Relationship: Director
Address: 500 BOYLSTON STREET, SUITE 1350, BOSTON
Signature: /s/ Adi Osovsky, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VOR transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +57,162
Change %
Price: $0.000000^*
Shares after: 57,162
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 57,162
Exercise price: $14.09
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.